1d
MedPage Today on MSNHigh Price of GLP-1 Agents Tip Cost-Benefit Scale UnfavorablyTirzepatide and semaglutide were associated with larger QALY gains (incremental gains of 0.35 and 0.25 over lifestyle ...
2don MSN
To be a person in the year 2025 is to encounter, in one way or another, the marketing onslaught for compounded ...
G lucagon-like peptide-1 receptor agonists, aka GLP-1 agonists, such as semaglutide -- better known as Ozempic -- have ...
The Maryland-based biopharma joins Eli Lilly and Novo Nordisk in trialing a GLP-1 agonist for alcohol- and liver-related ...
GLP-1 therapy is a groundbreaking approach in the treatment of obesity and metabolic health issues. GLP-1, or glucagon-like ...
While drug developers work to mitigate the side effects associated with GLP-1–based obesity drugs, recent studies reveal that ...
Anti-obesity drugs are only part of the larger treatment plan for most patients. Exercise and nutrition are also keys.
2d
Zacks Investment Research on MSNNVO Stock Slips 4% as Roche Inks Obesity Drug Deal With ZealandNovo Nordisk’s NVO stock declined 4.3% on Wednesday after Roche RHHBY announced a license and collaboration deal worth $5.3 ...
As it gets harder to offer compounded GLP-1s, many telehealth companies are pivoting to hormone replacement therapy.
Increasing access to these effective evidence-based treatments would benefit our society as a whole, not just those impacted ...
With increasing demand and higher costs, ensuring appropriate patient access is more critical than ever and 2025 will likely ...
A Columbia University dermatologist argues that physicians in her specialty should be on the lookout for metabolic syndrome ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results